Pure Global AI
NCT06374901Not yet recruiting

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

A Multicenter, Prospective Phase II Clinical Study of Tislelizumab in Combination With Chemotherapy for the Perioperative Treatment of Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Xiangdong ChengPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
Tislelizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Xiangdong Cheng
Funder
Zhejiang Cancer Hospital
Location
Hangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 25, 2024
End date
Mar 31, 2028
Enrollment
134 participants
Primary outcome

MRP (Main pathological response)

Summary

To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy
 in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced
 gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response
 rate (MPR).

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06374901
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06374901 through Pure Global AI's free database. This Phase 2 trial is sponsored by Xiangdong Cheng and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 134 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.